AUM Cardiovascular finishes pivotal trial enrollment

AUM Cardiovascular said last week it completed enrollment for the pivotal study of its CADence handheld heart disease diagnostics device.

Aum’s Cadence is designed to identify obstructions in the coronary arteries by detecting acoustic signals generated by the turbulence created as blood flows past the obstruction, according to the company’s site. The company’s name is based on a Sanskrit syllable meaning “to make a continuous low humming sound,” akin to the information the Cadence device is designed to extract from diseased coronary arteries, the company says.

The Northfield, Minn.-based company said it’s taken 3 years to recruit the over 1,000 patients for the trial.

Aum Cardiovascular was founded by CEO Marie Johnson after the unexpected death of her husband from a heart attack at age 41.

MassDevice.com spoke to Johnson at the DeviceTalks: Minnesota event in September about her experience creating and guiding the med-tech startup, which has now transitioned into clinical trials.

In July, Aum Cardiovascular said in a regulatory filing that it raised $5 million of a hoped-for $6.3 million funding push for the Cadence.

The post AUM Cardiovascular finishes pivotal trial enrollment appeared first on MassDevice.

from MassDevice http://ift.tt/1SxTnOE